Detection of Newly Secreted Antibodies Predicts Nonrecurrence in Primary Clostridioides difficile Infection.
Natalie S Haddad, Sophia Nozick, Geena Kim, Shant Ohanian, Colleen S Kraft, Paulina A Rebolledo, Yun Wang, Hao Wu, Adam Bressler, Sang Nguyet Thi Le, Merin Kuruvilla, Martin C Runnstrom, Richard P Ramonell, L Edward Cannon, F Eun-Hyung Lee, John L Daiss
Author Information
Natalie S Haddad: MicroB-plex, Inc., Atlanta, GA, USA. ORCID
Sophia Nozick: MicroB-plex, Inc., Atlanta, GA, USA.
Geena Kim: MicroB-plex, Inc., Atlanta, GA, USA.
Shant Ohanian: MicroB-plex, Inc., Atlanta, GA, USA.
Colleen S Kraft: Department of Pathology and Laboratory Medicine, Emory University School of Medicinegrid.471395.d, Atlanta, GA, USA. ORCID
Paulina A Rebolledo: Hubert Department of Global Health, Rollins School of Public Health, Emory Universitygrid.471395.d, Atlanta, GA, USA. ORCID
Yun Wang: Department of Pathology and Laboratory Medicine, Emory University School of Medicinegrid.471395.d, Atlanta, GA, USA.
Hao Wu: Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory Universitygrid.471395.d, Atlanta, GA, USA.
Adam Bressler: Infectious Disease Specialists of Atlanta, Decatur, GA, USA.
Sang Nguyet Thi Le: Pulmonary, Allergy, Critical Care & Sleep Medicine, Emory Universitygrid.471395.d, Atlanta, GA, USA.
Merin Kuruvilla: Pulmonary, Allergy, Critical Care & Sleep Medicine, Emory Universitygrid.471395.d, Atlanta, GA, USA.
Martin C Runnstrom: Pulmonary, Allergy, Critical Care & Sleep Medicine, Emory Universitygrid.471395.d, Atlanta, GA, USA.
Richard P Ramonell: Pulmonary, Allergy, Critical Care & Sleep Medicine, Emory Universitygrid.471395.d, Atlanta, GA, USA.
L Edward Cannon: MicroB-plex, Inc., Atlanta, GA, USA.
F Eun-Hyung Lee: MicroB-plex, Inc., Atlanta, GA, USA.
John L Daiss: MicroB-plex, Inc., Atlanta, GA, USA. ORCID
Within 8 weeks of primary Clostridioides difficile infection (CDI), as many as 30% of patients develop recurrent disease with the associated risks of multiple relapses, morbidity, and economic burden. There are no clear clinical correlates or validated biomarkers that can predict recurrence during primary infection. This study demonstrated the potential of a simple test for identifying hospitalized CDI patients at low risk for disease recurrence. Forty-six hospitalized CDI patients were enrolled at Emory University Hospitals. Samples of serum and a novel matrix from circulating plasmablasts called "medium-enriched for newly synthesized antibodies" (MENSA) were collected during weeks 1, 2, and 4. Antibodies specific for 10 C. difficile antigens were measured in each sample. Among the 46 C. difficile-infected patients, 9 (19.5%) experienced recurrence within 8 weeks of primary infection. Among the 37 nonrecurrent patients, 23 (62%; 23/37) had anti-C. difficile MENSA antibodies specific for any of the three toxin antigens: TcdB-CROP, TcdBvir-CROP, and/or CDTb. Positive MENSA responses occurred early (within the first 12 days post-symptom onset), including six patients who never seroconverted. A similar trend was observed in serum responses, but they peaked later and identified fewer patients (51%; 19/37). In contrast, none (0%; 0/9) of the patients who subsequently recurred after hospitalization produced antibodies specific for any of the three C. difficile toxin antigens. Thus, patients with a negative early MENSA response against all three C. difficile toxin antigens had a 19-fold greater relative risk of recurrence. MENSA and serum levels of immunoglobulin A (IgA) and/or IgG antibodies for three C. difficile toxins have prognostic potential. These immunoassays measure nascent immune responses that reduce the likelihood of recurrence thereby providing a biomarker of protection from recurrent CDI. Patients who are positive by this immunoassay are unlikely to suffer a recurrence. Early identification of patients at risk for recurrence by negative MENSA creates opportunities for targeted prophylactic strategies that can reduce the incidence, cost, and morbidity due to recurrent CDI.
